Cited 6 times in
Cost-Effectiveness of Rate- and Rhythm-Control Drugs for Treating Atrial Fibrillation in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김우진 | - |
dc.contributor.author | 김창수 | - |
dc.contributor.author | 정보영 | - |
dc.contributor.author | 김민 | - |
dc.date.accessioned | 2020-02-11T06:23:35Z | - |
dc.date.available | 2020-02-11T06:23:35Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/174657 | - |
dc.description.abstract | PURPOSE: Although the economic and mortality burden of atrial fibrillation (AF) is substantial, it remains unclear which treatment strategies for rate and rhythm control are most cost-effective. Consequently, economic factors can play an adjunctive role in guiding treatment selection. MATERIALS AND METHODS: We built a Markov chain Monte Carlo model using the Korean Health Insurance Review & Assessment Service database. Drugs for rate control and rhythm control in AF were analyzed. Cost-effective therapies were selected using a cost-effectiveness ratio, calculated by net cost and quality-adjusted life years (QALY). RESULTS: In the National Health Insurance Service data, 268149 patients with prevalent AF (age ≥18 years) were identified between January 1, 2013 and December 31, 2015. Among them, 212459 and 55690 patients were taking drugs for rate and rhythm control, respectively. Atenolol cost $714/QALY. Among the rate-control medications, the cost of propranolol was lowest at $487/QALY, while that of carvedilol was highest at $1363/QALY. Among the rhythm-control medications, the cost of pilsicainide was lowest at $638/QALY, while that of amiodarone was highest at $986/QALY. Flecainide and propafenone cost $834 and $830/QALY, respectively. The cost-effectiveness threshold of all drugs was lower than $30000/QALY. Compared with atenolol, the rate-control drugs propranolol, betaxolol, bevantolol, bisoprolol, diltiazem, and verapamil, as well as the rhythm-control drugs sotalol, pilsicainide, flecainide, propafenone, and dronedarone, showed better incremental cost-effectiveness ratios. CONCLUSION: Propranolol and pilsicainide appear to be cost-effective in patients with AF in Korea assuming that drug usage or compliance is the same. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Yonsei University | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Cost-Effectiveness of Rate- and Rhythm-Control Drugs for Treating Atrial Fibrillation in Korea | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Preventive Medicine and Public Health (예방의학교실) | - |
dc.contributor.googleauthor | Min Kim | - |
dc.contributor.googleauthor | Woojin Kim | - |
dc.contributor.googleauthor | Changsoo Kim | - |
dc.contributor.googleauthor | Boyoung Joung | - |
dc.identifier.doi | 10.3349/ymj.2019.60.12.1157 | - |
dc.contributor.localId | A05662 | - |
dc.contributor.localId | A01042 | - |
dc.contributor.localId | A03609 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 31769246 | - |
dc.subject.keyword | Atrial fibrillation | - |
dc.subject.keyword | QALY | - |
dc.subject.keyword | cost effectiveness | - |
dc.subject.keyword | drugs | - |
dc.contributor.alternativeName | Kim, Woojin | - |
dc.contributor.affiliatedAuthor | 김우진 | - |
dc.contributor.affiliatedAuthor | 김창수 | - |
dc.contributor.affiliatedAuthor | 정보영 | - |
dc.citation.volume | 60 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 1157 | - |
dc.citation.endPage | 1163 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.60(12) : 1157-1163, 2019 | - |
dc.identifier.rimsid | 63494 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.